SAN FRANCISCO (Thomson Financial) - Array BioPharma Inc. late Monday
reported a third-quarter net loss of $24.4 million, or 51 cents a share,
narrower by a penny than the mean 52-cent loss estimate of analysts polled by
Thomson Reuters.
The net loss in the prior-year period was $14.1 million, or 35 cents a
share, a year earlier, the Boulder, Colo.-based biopharmaceutical company said.
Revenue for the quarter ended March 31 fell to $7.71 million from $10.4
million a year earlier, above the mean Street view of $7.26 million.
The stock closed the regular session down 30 cents, or 4.8%, at $5.97.
Brigid Gaffikin
bg/kh
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|